SA001 for Sjögren's Dry Mouth: What the Eight-Week Pilot Found

A drug designed to improve absorption still has to show that people feel or function better. SA001’s early Sjögren’s study tested that question with both a saliva measurement and a symptom questionnaire.

What was tested, and what changed?

SA001 is a rebamipide prodrug designed to improve absorption. The 2026 phase 2a report randomized 28 women, aged 41–75, with primary Sjögren’s to three oral dose groups or placebo for eight weeks.¹

Mouth outcomes used 21 per-protocol participants, three to eight per group. Neither unstimulated salivary flow nor Xerostomia Inventory scores differed significantly between groups: P=0.5017 and P=0.0586, respectively. Dose response was inconsistent.¹

The exploratory trial cannot settle efficacy or uncommon harms. The report lists four Samjin employees among its authors and declares no external funding.¹

Why check the registry as well as the paper?

The NCT05269810 registry identifies Samjin Pharmaceutical as sponsor and lists the trial as completed, with actual completion in March 2022. Its latest posted update was February 2023. This is a report of a finished early study, not a notice that enrollment is open.²

The registry lists several ocular and oral measures as primary outcomes, rather than one main efficacy measure. It should be read alongside the report; a collection of measurements does not justify selecting the most favorable result as proof.²

Did ordinary rebamipide already settle the question?

No. A 2009 Japanese report randomized 104 people with Sjögren’s syndrome to oral rebamipide or placebo for eight weeks. At the final visit, symptom improvement was 46.9% versus 39.1%, without a significant difference. The overall saliva result, measured by the Saxon test, also did not differ significantly.³

Some subgroup findings favored rebamipide, including salivary secretion in primary Sjögren’s. But the study made multiple exploratory comparisons without adjusting for multiplicity. Selecting a favorable subgroup does not erase the overall result or prove that the newer prodrug will work.³

What belongs in the care plan while research continues?

The NIDCR’s February 2026 guidance explains that Sjögren’s dry mouth increases cavity, tooth-loss and mouth-infection risk. It describes saliva substitutes and prescription saliva stimulants, and recommends asking a dentist about fluoride rinse, nighttime gel or varnish. Symptom relief and protecting teeth are separate treatment needs.⁴

At the appointment, describe what dryness prevents: eating a cracker, finishing a conversation, sleeping without waking for water. Ask how the clinician will measure progress and which dental protections need their own schedule. A saliva-flow result and a comfort score answer different questions.

The “Supporting Saliva” section of Is It My Breath? separates saliva stimulation from substitutes and includes the dentist discussion about extra fluoride. Use that discussion alongside your current medical plan. Our cevimeline trial article examines a different medicine with its own evidence and prescribing limits.